All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Visual abstract | Efficacy of guselkumab in treating regional psoriasis and psoriatic arthritis: post-hoc analyses of VOYAGE 1 and 2
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing post-hoc analyses of the VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244) trials assessing the efficacy of guselkumab in the treatment of regional psoriasis and psoriatic arthritis (PsA).
PsA is a chronic inflammatory condition with skin and musculoskeletal involvement. Patients with PsA and nail psoriasis have a poor quality of life, experiencing higher disease activity that makes treatment challenging. Guselkumab is an inhibitor of the p19 subunit of interleukin-23, approved for the treatment of moderate-to-severe psoriasis and active PsA in adults; guselkumab has demonstrated efficacy across multiple PsA domains in the DISCOVER-1 and DISCOVER-2 trials. The post-hoc analyses by Orbai et al.1 demonstrated that guselkumab was effective in treating psoriasis of nails, scalp, palms, and/or soles, and improved quality of life in patients with psoriasis and PsA.
- Orbai AM, Chakravarty SD, You Y, et al. Efficacy of guselkumab in treating nails, scalp, hands, and feet in patients with psoriasis and self-reported psoriatic arthritis. Dermatol Ther (Heidelb). 2023;13(11):2859-2868. DOI: 1007/s13555-023-01012-z
Your opinion matters
6 votes - 85 days left ...
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox